Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina

Jorge Elgart (), Joaquin Caporale (), Lorena Gonzalez (), Eleonora Aiello (), Maximiliano Waschbusch () and Juan Gagliardino ()

Health Economics Review, 2013, vol. 3, issue 1, 1-9

Abstract: According to the criteria proposed by the Commission on Macroeconomics and Health, the use of the combination SAXA + MET is highly cost-effective in Argentina. Copyright Elgart et al.; licensee Springer. 2013

Keywords: Type 2 Diabetes treatment; Saxagliptin; DPP-4 inhibitors; Pharmacoeconomics; Cost-effectiveness analysis; Latin America; Argentina (search for similar items in EconPapers)
Date: 2013
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (6)

Downloads: (external link)
http://hdl.handle.net/10.1186/2191-1991-3-11 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:3:y:2013:i:1:p:1-9:10.1186/2191-1991-3-11

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/2191-1991-3-11

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().